Infliximab dependency is related to decreased surgical rates in adult Crohn's disease patients

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 10, 2010, Pages 1196-1203

  Pedersen, Natalia ^a   Duricova, Dana ^c   Lenicek, Martin ^d   Elkjaer, Margarita ^a   Bortlik, Martin ^e   Andersen, Paal Skytt ^b   Vitek, Libor ^d,e   Davidsen, Bogi ^b   Wewer, Vibeke ^a   Lukas, Milan ^c,d   Munkholm, Pia ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b SLAGELSE HOSPITAL   (Denmark)

^c Fourth Department of Internal Medicine   (Denmark)

^d First Faculty of Medicine   (Denmark)

^e CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Crohn's disease; genotype; infliximab dependency; phenotype; surgery

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ADULT; ADULT DISEASE; ALLELE; ARTICLE; COLORECTAL SURGERY; CROHN DISEASE; DRUG DEPENDENCE; DRUG DOSE INCREASE; FEMALE; GENETIC ANALYSIS; HUMAN; INTESTINE SURGERY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CROHN DISEASE; CZECH REPUBLIC; DENMARK; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; GASTROINTESTINAL AGENTS; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957559042     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32833dde2e     Document Type: Article

References (38)

1. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002;359:1541-1549.
2. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-653.
3. Domenech E, Zabana Y, Garcia-Planella E, Lopez San RA, Nos P, Ginard D, et al. Clinical outcome of newly diagnosed Crohn's disease: a comparative, retrospective study before and after infliximab availability. Aliment Pharmacol Ther 2010;31:233-239.
4. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-260.
5. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-362.
6. De Ridder L, Rings EH, Damen GM, Kneepkens CM, Schweizer JJ, Kokke FT, et al. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis 2008;14:353-358.
7. Duricova D, Pedersen N, Lenicek M, Hradsky O, Bronsky J, Adamcova M, et al. Infliximab Dependency in children with Crohn's disease. Aliment Pharmacol Ther 2009;29:792-799.
8. Wewer V, Riis L, Vind I, Husby S, Munkholm P, Paerregaard A. Infliximab dependency in a national cohort of children with Crohn's disease. J Pediatr Gastroenterol Nutr 2006;42:40-45.
9. Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008;6:1212-1217.
10. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009;30:253-264.
11. Zabana Y, Domenech E, Manosa M, Garcia-Planella E, Bernal I, Cabre E, et al. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice. Aliment Pharmacol Ther 2010;31:553-560.
12. Bourikas LA, Kourbeti IS, Koutsopoulos AV, Koutroubakis IE. Disseminated tuberculosis in a Crohn's disease patient on anti-TNF alpha therapy despite chemoprophylaxis. Gut 2008;57:425-426.
13. Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007;52:1481-1484.
14. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104.
15. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-267.
16. Thayu M, Markowitz JE, Mamula P, Russo PA, Muinos WI, Baldassano RN. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005;40:220-222.
17. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001;344:1099-1100.
18. Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006;55(Suppl 1):i1-i15.
19. Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008;135:1106-1113.
20. Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006;101:1274-1282.
21. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-873. (Pubitemid 46454266)
22. Domenech E, Hinojosa J, Nos P, Garcia-Planella E, Cabre E, Bernal I, et al. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? Aliment Pharmacol Ther 2005;22:1107-1113.
23. Kevans D, Keegan D, Mulcahy HE, O'Donoghue DP. Infliximab therapy in Crohn's disease: a pragmatic approach? Aliment Pharmacol Ther 2006;24:351-359.
24. Taylor KD, Plevy SE, Yang H, Landers CJ, Barry MJ, Rotter JI, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 2001;120:1347-1355.
25. Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, van SN, et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther 2005;22:613-626.
26. Gonzalez S, Rodrigo L, Martinez-Borra J, Lopez-Vazquez A, Fuentes D, Nino P, et al. TNF-alpha-308A promoter polymorphism is associated with enhanced TNF-alpha production and inflammatory activity in Crohn's patients with fistulizing disease. Am J Gastroenterol 2003;98:1101-1106.
27. Louis E, Vermeire S, Rutgeerts P, De VM, Van GA, Pescatore P, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism. Scand J Gastroenterol 2002;37:818-824.
28. Sykora J, Subrt I, Didek P, Siala K, Schwarz J, Machalova V, et al. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position-308 G-A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease. J Pediatr Gastroenterol Nutr 2006;42:479-487.
29. Mascheretti S, Hampe J, Kuhbacher T, Herfarth H, Krawczak M, Folsch UR, et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J 2002;2:127-136.
30. D'Haens G, Baert F, van AG, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomized trial. Lancet 2008;371:660-667.
31. Froslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412-422.
32. Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol 2002;35:151-156.
33. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-413. (Pubitemid 38182297)
34. Ruemmele FM, Lachaux A, Cezard JP, Morali A, Maurage C, Ginies JL, et al. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm Bowel Dis 2009;15:388-394.
35. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58:501-508.
36. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-630.
37. Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel J, et al. The second European evidence-based Consensus on the diagnostics and management of Crohn's disease: current management [Abstract]. Journal of Crohn's and Colitis 2010;4:28-62.
38. Tung J, Loftus EV Jr, Freese DK, El-Youssef M, Zinsmeister AR, Melton LJ III, et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2006;12:1093-1100.